Enfortumab vedotin (Padcev)
New indication (Carcinoma, Transitional Cell, Urologic Neoplasms). The wording is on the EMA page.
Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
New indication (Carcinoma, Transitional Cell, Urologic Neoplasms). The wording is on the EMA page.